Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Pancreatic Cancer Treatments Poised for Major Advances in 2024 By: FinancialNewsMedia February 07, 2024 at 08:55 AM EST FN Media Group Presents USA News Group News Commentary Vancouver, BC – February 7, 2024 – USA News Group – One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer. As well, the deadly disease showed pancreatic cancer rates rising faster among women, causing increased alarm amongst doctors. Thankfully, 2023 also gave a lot of hope in terms of new treatments for the market that could reach US$36 billion by 2036, such as a potential mRNA vaccine, and other developments from biotech companies to lead into 2024, like Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Incyte Corporation (NASDAQ:INCY), Tango Therapeutics, Inc. (NASDAQ:TNGX), RayzeBio, Inc. (NASDAQ:RYZB) and its buyer Bristol-Myers Squibb Company (NYSE:BMY). After closing out 2022 with another fast track designation, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) and its flagship asset pelareorep continues to make strides in the battle against pancreatic cancer. This recognition came after pelareorep plus atezolizumab with gemcitabine and nab-paclitaxel achieved an impressive objective response rate (ORR) of 69%. The results were enough to garner the support of the Pancreatic Cancer Action Network (PanCAN), who selected pelareorep to receive the US$5 million Therapeutic Accelerator Award. “2023 was an outstanding year for Oncolytics and the development of pelareorep as a potential cancer therapy,” said Dr. Matt Coffey, President and CEO of Oncolytics. “To date, we have studied pelareorep in more than 1,100 patients, and it has been shown to be well-tolerated with mild side effects. We believe our cash balance and strong data, supported by our active business development program, position us well for 2024.” Most recently, Oncolytics added accomplished biopharmaceutical executive Pat Andrews to its Board of Directors. She comes with a track record of success in corporate strategy, first-in-class and first-for-the-company new product commercializations and business development, and a resume that includes 17 years with Pfizer leading a $900-million portfolio at the time, and later serving as CEO of Sumitomo Pharma Oncology (SMP), and as the Chief Commercial Officer for Incyte Corporation (NASDAQ:INCY), where she led the company through the launch of Jakafi, Incyte’s first commercial product. “I am honored to join the Oncolytics board at this exciting time for the organization as it advances pelareorep toward registrational studies,” said Ms. Andrews. “Promising recent results from the BRACELET-1 and GOBLET studies suggest that pelareorep has the potential to make an important contribution to cancer care, and I look forward to working with my fellow board members in addition to Dr. Coffey and the Executive Team to execute Oncolytics’ clinical and corporate development plans.” Andrews’s previous employer Incyte Corporation (NASDAQ:INCY) also continues to be active in the pancreatic cancer space itself. Like Oncolytics Biotech, Incyte is also involved with PanCAN in bringing potentially pioneering treatment options to patients. Now, the market is watching out for the potential future approval of Incyte’s INCA-33890 for pancreatic cancer, which is currently in Phase I. INCA-33890 is a novel PD-1x TGFbR2 bispecific antibody designed to conditionally antagonize TGF signaling in primary immune cells co-expressing PD-1. Through a licensing deal with Swedish pharmaceutical company Medivir, Tango Therapeutics, Inc. (NASDAQ:TNGX) received FDA clearance on its Investigational New Drug application for TNG348 back in September 2023. Now, in early 2024, Tango has dosed the first patient for the drug in a phase 1/2 clinical study. Tango licensed TNG348 from Medivir back in 2020. TNG348 is a novel USP1 inhibitor for the treatment of BRCA1/2-mutant and other homologous recombination deficiency (HRD)+ cancers. HRD+ cancers, including BRCA1/2 mutations, represent 5% of pancreatic cancers. “The preclinical data generated by Tango for TNG348 is promising and dosing the first patient in a clinical study is encouraging for patients with HRD+ cancers,” said Jens Lindberg, CEO of Medivir. “The efforts undertaken by Tango to develop TNG348 into a clinical-staged drug are impressive and we will continue to follow the clinical development of TNG348 with great anticipation.” Closing out 2023, Bristol-Myers Squibb Company (NYSE:BMY) struck a deal for roughly $4.1 billion to buy RayzeBio, Inc. (NASDAQ:RYZB), with the highlight of the deal being RYZ101, which is being tested in late-stage studies for a rare type of pancreatic cancer. It’s a drug that uses radioactive particles to kill tumor cells. “[The RayzeBio acquisition] further strengthens our growth opportunities in the back half of the decade and beyond,” said Chris Boerner, newly-appointed CEO of BMY. “Acquiring RayzeBio’s differentiated actinium-based radiopharmaceutical platform will establish Bristol Myers Squibb’s presence in one of the most promising and fastest-growing new modalities for the treatment of patients with solid tumors – delivering radioactive payloads to cancer cells in a targeted manner,” added Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer, Drug Development of Bristol Myers Squibb. “In addition, RayzeBio’s platform has the potential to be a significant IND engine, generating several therapeutic candidates in the future by leveraging our global drug development capabilities and infrastructure.” READ MORE HERE: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ Article Source: USA News Group http://USAnewsgroup.com info@usanewsgroup.com DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. USA News Group is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein. The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release. This release contains “forward-loking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements. Media Contact Information: FN Media Group, LLC Media Contact e-mail: editor@financialnewsmedia.com U.S. Phone: +1(954)345-0611 SOURCE USA News Group The post Pancreatic Cancer Treatments Poised for Major Advances in 2024 appeared first on Financial News Media. Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Pancreatic Cancer Treatments Poised for Major Advances in 2024 By: FinancialNewsMedia February 07, 2024 at 08:55 AM EST FN Media Group Presents USA News Group News Commentary Vancouver, BC – February 7, 2024 – USA News Group – One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer. As well, the deadly disease showed pancreatic cancer rates rising faster among women, causing increased alarm amongst doctors. Thankfully, 2023 also gave a lot of hope in terms of new treatments for the market that could reach US$36 billion by 2036, such as a potential mRNA vaccine, and other developments from biotech companies to lead into 2024, like Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Incyte Corporation (NASDAQ:INCY), Tango Therapeutics, Inc. (NASDAQ:TNGX), RayzeBio, Inc. (NASDAQ:RYZB) and its buyer Bristol-Myers Squibb Company (NYSE:BMY). After closing out 2022 with another fast track designation, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) and its flagship asset pelareorep continues to make strides in the battle against pancreatic cancer. This recognition came after pelareorep plus atezolizumab with gemcitabine and nab-paclitaxel achieved an impressive objective response rate (ORR) of 69%. The results were enough to garner the support of the Pancreatic Cancer Action Network (PanCAN), who selected pelareorep to receive the US$5 million Therapeutic Accelerator Award. “2023 was an outstanding year for Oncolytics and the development of pelareorep as a potential cancer therapy,” said Dr. Matt Coffey, President and CEO of Oncolytics. “To date, we have studied pelareorep in more than 1,100 patients, and it has been shown to be well-tolerated with mild side effects. We believe our cash balance and strong data, supported by our active business development program, position us well for 2024.” Most recently, Oncolytics added accomplished biopharmaceutical executive Pat Andrews to its Board of Directors. She comes with a track record of success in corporate strategy, first-in-class and first-for-the-company new product commercializations and business development, and a resume that includes 17 years with Pfizer leading a $900-million portfolio at the time, and later serving as CEO of Sumitomo Pharma Oncology (SMP), and as the Chief Commercial Officer for Incyte Corporation (NASDAQ:INCY), where she led the company through the launch of Jakafi, Incyte’s first commercial product. “I am honored to join the Oncolytics board at this exciting time for the organization as it advances pelareorep toward registrational studies,” said Ms. Andrews. “Promising recent results from the BRACELET-1 and GOBLET studies suggest that pelareorep has the potential to make an important contribution to cancer care, and I look forward to working with my fellow board members in addition to Dr. Coffey and the Executive Team to execute Oncolytics’ clinical and corporate development plans.” Andrews’s previous employer Incyte Corporation (NASDAQ:INCY) also continues to be active in the pancreatic cancer space itself. Like Oncolytics Biotech, Incyte is also involved with PanCAN in bringing potentially pioneering treatment options to patients. Now, the market is watching out for the potential future approval of Incyte’s INCA-33890 for pancreatic cancer, which is currently in Phase I. INCA-33890 is a novel PD-1x TGFbR2 bispecific antibody designed to conditionally antagonize TGF signaling in primary immune cells co-expressing PD-1. Through a licensing deal with Swedish pharmaceutical company Medivir, Tango Therapeutics, Inc. (NASDAQ:TNGX) received FDA clearance on its Investigational New Drug application for TNG348 back in September 2023. Now, in early 2024, Tango has dosed the first patient for the drug in a phase 1/2 clinical study. Tango licensed TNG348 from Medivir back in 2020. TNG348 is a novel USP1 inhibitor for the treatment of BRCA1/2-mutant and other homologous recombination deficiency (HRD)+ cancers. HRD+ cancers, including BRCA1/2 mutations, represent 5% of pancreatic cancers. “The preclinical data generated by Tango for TNG348 is promising and dosing the first patient in a clinical study is encouraging for patients with HRD+ cancers,” said Jens Lindberg, CEO of Medivir. “The efforts undertaken by Tango to develop TNG348 into a clinical-staged drug are impressive and we will continue to follow the clinical development of TNG348 with great anticipation.” Closing out 2023, Bristol-Myers Squibb Company (NYSE:BMY) struck a deal for roughly $4.1 billion to buy RayzeBio, Inc. (NASDAQ:RYZB), with the highlight of the deal being RYZ101, which is being tested in late-stage studies for a rare type of pancreatic cancer. It’s a drug that uses radioactive particles to kill tumor cells. “[The RayzeBio acquisition] further strengthens our growth opportunities in the back half of the decade and beyond,” said Chris Boerner, newly-appointed CEO of BMY. “Acquiring RayzeBio’s differentiated actinium-based radiopharmaceutical platform will establish Bristol Myers Squibb’s presence in one of the most promising and fastest-growing new modalities for the treatment of patients with solid tumors – delivering radioactive payloads to cancer cells in a targeted manner,” added Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer, Drug Development of Bristol Myers Squibb. “In addition, RayzeBio’s platform has the potential to be a significant IND engine, generating several therapeutic candidates in the future by leveraging our global drug development capabilities and infrastructure.” READ MORE HERE: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ Article Source: USA News Group http://USAnewsgroup.com info@usanewsgroup.com DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. USA News Group is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein. The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release. This release contains “forward-loking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements. Media Contact Information: FN Media Group, LLC Media Contact e-mail: editor@financialnewsmedia.com U.S. Phone: +1(954)345-0611 SOURCE USA News Group The post Pancreatic Cancer Treatments Poised for Major Advances in 2024 appeared first on Financial News Media.
FN Media Group Presents USA News Group News Commentary Vancouver, BC – February 7, 2024 – USA News Group – One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer. As well, the deadly disease showed pancreatic cancer rates rising faster among women, causing increased alarm amongst doctors. Thankfully, 2023 also gave a lot of hope in terms of new treatments for the market that could reach US$36 billion by 2036, such as a potential mRNA vaccine, and other developments from biotech companies to lead into 2024, like Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Incyte Corporation (NASDAQ:INCY), Tango Therapeutics, Inc. (NASDAQ:TNGX), RayzeBio, Inc. (NASDAQ:RYZB) and its buyer Bristol-Myers Squibb Company (NYSE:BMY). After closing out 2022 with another fast track designation, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) and its flagship asset pelareorep continues to make strides in the battle against pancreatic cancer. This recognition came after pelareorep plus atezolizumab with gemcitabine and nab-paclitaxel achieved an impressive objective response rate (ORR) of 69%. The results were enough to garner the support of the Pancreatic Cancer Action Network (PanCAN), who selected pelareorep to receive the US$5 million Therapeutic Accelerator Award. “2023 was an outstanding year for Oncolytics and the development of pelareorep as a potential cancer therapy,” said Dr. Matt Coffey, President and CEO of Oncolytics. “To date, we have studied pelareorep in more than 1,100 patients, and it has been shown to be well-tolerated with mild side effects. We believe our cash balance and strong data, supported by our active business development program, position us well for 2024.” Most recently, Oncolytics added accomplished biopharmaceutical executive Pat Andrews to its Board of Directors. She comes with a track record of success in corporate strategy, first-in-class and first-for-the-company new product commercializations and business development, and a resume that includes 17 years with Pfizer leading a $900-million portfolio at the time, and later serving as CEO of Sumitomo Pharma Oncology (SMP), and as the Chief Commercial Officer for Incyte Corporation (NASDAQ:INCY), where she led the company through the launch of Jakafi, Incyte’s first commercial product. “I am honored to join the Oncolytics board at this exciting time for the organization as it advances pelareorep toward registrational studies,” said Ms. Andrews. “Promising recent results from the BRACELET-1 and GOBLET studies suggest that pelareorep has the potential to make an important contribution to cancer care, and I look forward to working with my fellow board members in addition to Dr. Coffey and the Executive Team to execute Oncolytics’ clinical and corporate development plans.” Andrews’s previous employer Incyte Corporation (NASDAQ:INCY) also continues to be active in the pancreatic cancer space itself. Like Oncolytics Biotech, Incyte is also involved with PanCAN in bringing potentially pioneering treatment options to patients. Now, the market is watching out for the potential future approval of Incyte’s INCA-33890 for pancreatic cancer, which is currently in Phase I. INCA-33890 is a novel PD-1x TGFbR2 bispecific antibody designed to conditionally antagonize TGF signaling in primary immune cells co-expressing PD-1. Through a licensing deal with Swedish pharmaceutical company Medivir, Tango Therapeutics, Inc. (NASDAQ:TNGX) received FDA clearance on its Investigational New Drug application for TNG348 back in September 2023. Now, in early 2024, Tango has dosed the first patient for the drug in a phase 1/2 clinical study. Tango licensed TNG348 from Medivir back in 2020. TNG348 is a novel USP1 inhibitor for the treatment of BRCA1/2-mutant and other homologous recombination deficiency (HRD)+ cancers. HRD+ cancers, including BRCA1/2 mutations, represent 5% of pancreatic cancers. “The preclinical data generated by Tango for TNG348 is promising and dosing the first patient in a clinical study is encouraging for patients with HRD+ cancers,” said Jens Lindberg, CEO of Medivir. “The efforts undertaken by Tango to develop TNG348 into a clinical-staged drug are impressive and we will continue to follow the clinical development of TNG348 with great anticipation.” Closing out 2023, Bristol-Myers Squibb Company (NYSE:BMY) struck a deal for roughly $4.1 billion to buy RayzeBio, Inc. (NASDAQ:RYZB), with the highlight of the deal being RYZ101, which is being tested in late-stage studies for a rare type of pancreatic cancer. It’s a drug that uses radioactive particles to kill tumor cells. “[The RayzeBio acquisition] further strengthens our growth opportunities in the back half of the decade and beyond,” said Chris Boerner, newly-appointed CEO of BMY. “Acquiring RayzeBio’s differentiated actinium-based radiopharmaceutical platform will establish Bristol Myers Squibb’s presence in one of the most promising and fastest-growing new modalities for the treatment of patients with solid tumors – delivering radioactive payloads to cancer cells in a targeted manner,” added Samit Hirawat, M.D., Executive Vice President, Chief Medical Officer, Drug Development of Bristol Myers Squibb. “In addition, RayzeBio’s platform has the potential to be a significant IND engine, generating several therapeutic candidates in the future by leveraging our global drug development capabilities and infrastructure.” READ MORE HERE: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ Article Source: USA News Group http://USAnewsgroup.com info@usanewsgroup.com DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. USA News Group is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein. The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release. This release contains “forward-loking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements. Media Contact Information: FN Media Group, LLC Media Contact e-mail: editor@financialnewsmedia.com U.S. Phone: +1(954)345-0611 SOURCE USA News Group The post Pancreatic Cancer Treatments Poised for Major Advances in 2024 appeared first on Financial News Media.
